Head OfficeNovartis International AGCH-4002 BaselSwitzerland
+41 61 324 11 11+41 61 324 80 01Monday - Friday,8:30 - 17:00, GMT+1(Central European Time)
More information
Novartis International AGInvestor RelationsP.O. BoxCH-4002 BaselSwitzerland
+41 61 324 79 44investor.relations@novartis.com
Global Media RelationsEric AlthoffBasel, Switzerland
+41 61 324 7999eric.althoff@novartis.com
17-May-2012Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients
10-May-2012New data among 200 Lucentis® abstracts at ARVO show low number of injections with Novartis drug required to achieve and maintain vision gains over 3 years in AMD and DME patients
07-May-2012Novartis drug pasireotide LAR shows superior efficacy compared to Sandostatin® LAR® in Phase III trial of patients with acromegaly
View all press releases
Sign up for email alerts
English newsfeed
German newsfeed
French newsfeed
Follow Novartis on Twitter
Alcon information center
Pharmaceutical products
Clinical pipeline
Management bios
December 13 oncology call presentation (1.9 MB)
Form 20-F 2011 (2.0 MB)
Corporate organizational structure (41 KB)
Stock performance
Novartis announced its results for the first quarter of 2012 on April 24 ยป